Navigation Links
Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment
Date:9/28/2007

CARMIEL, Israel, Sept. 28 /PRNewswire-FirstCall/ -- The Russell Investment Group has advised Protalix Biotherapeutics (Amex: PLX) that there will be a float weight adjustment effective after the close of trading on September 28, 2007 in the following indexes: Russell 2000, Russell 2000 Growth, Russell 2500, Russell 2500 Growth, Russell Global Small Cap, Russell 3000, Russell 3000 Growth, Russell Small Cap Completeness and the Russell Small Cap Completeness Growth.

About Protalix BioTherapeutics, Inc.

Protalix is a clinical stage biopharmaceutical company. Its goal is to become a fully integrated biopharmaceutical company focused on the development and commercialization of proprietary recombinant therapeutic proteins to be expressed through its proprietary plant cell based protein expression system, ProCellEx(TM). ProCellEx presents a proprietary method for the expression of recombinant proteins that Protalix believes is safe and scalable and will allow for the cost-effective, industrial-scale production of recombinant therapeutic proteins. Protalix has initiated enrollment and treatment of patients in its pivotal phase III clinical trial of its lead product candidate, prGCD, for enzyme replacement therapy of Gaucher disease, a lysosomal storage disorder in humans. The final design of the pivotal phase III clinical trial is based on an agreement reached by Protalix with the United States Food and Drug Administration, through its Special Protocol Assessment (SPA). Protalix is also advancing additional recombinant biopharmaceutical drug development programs.

Safe Harbor Statement:

To the extent that statements in this press release are not strictly historical, all such statements are forward-lookin
'/>"/>

SOURCE Protalix BioTherapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Russell Killer Bids To Halt Publication Of Mental Health Report
2. China Doubles Its Investment In AIDS/HIV Treatment.
3. Biocon To Raise Its Investment In Scotland
4. Cocoa Treats: Chocolates, as a Health Investment? Chew on this!
5. Varicose Vein Treatments Turn Out To Be A Viable Health Investment
6. WHO calls for big investment in tests for TB
7. China Opens Doors For Foreign Investments In Hospitals Care System
8. Fidel Castro Appeals for Investment in Health Rather Than in Arms
9. No link between blood groups and prostate cancer
10. Consumer group seeks Sibutramine ban
11. Suicide risk high in 12-17 Age Group

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...25/PRNewswire/-SentinelleMedicalInc.,aleadingmanuf...twarelaunchesasuiteofnewleadingedgeclinicalapplica...tthisyear,sRadiologicalSocietyofNorthAmerica(RSNA)...,HallA).Theapplicationsleveragetheuniquehighqualit...gcoilsandsupportmultipleimagingmodalitiesformulti-...
(Date:11/25/2009)...,Md.,Nov.25/PRNewswire-USNewswire/--AnarticlebyJan...luationandResearch,titled"ADifficultBalance-PainMa...2009issueofTheNewEnglandJournalofMedicine. ,, (.../FDALOGO ) ,, Inthearticle,WoodcockdiscussesFDA...onforthosewhoneeditandmanagingtherisksposedbyvario...
(Date:11/25/2009)...,Nov.25/PRNewswire/--TheBayAreaAirQualityManagemen... the Air Alert forThursday,November26,2...thersolidfuel,bothindoorsandoutdoors. ,, "Cold,...orrow,"saidJackBroadbent,executiveofficeroftheAirD...althoftheirneighborsandfellowcommunitymembersthisT...
(Date:11/25/2009)...s of testicular cancer who were treated with cispl...ts, including neurological side effects and Raynau...th chemotherapy, according to a new study publishe...al Cancer Institute . , Marianne Brydy, M.D., of...Hospital, in Bergen, Norway, and colleagues conduc...
(Date:11/25/2009)...covery that grew out of a collaboration between UC...r hope to the nearly 10 million Americans who suff...known as hardening of the arteries, peripheral art...blem in which narrowed arteries reduce blood flow ...ag for vascular disease, heart attack and stroke, ...
Breaking Medicine News(10 mins):Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 2Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 3Health News:Winter Spare the Air Alert in Effect for Thursday, November 26, 2009 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 3Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 4
...ial bond exists among siblings, even though they c...luding recognition from their parents. The relatio...ferent from that of with parents or partners. Most...ome more like partnerships, partly because childre...
... Colgan, Former chief Pennsylvania Lt. Gov. Cather... done to prevent the spread of HIV infection. She ...with HIV infections. // She has the view tha...vention of HIV/AIDS infection. Due to reduction in...
...aler which is capable of regulating the blood suga... and Drug Administration (FDA). // This inhaler wi...uffering from diabetes. The hand-held Exubera inha...out the size of an eyeglass case. The unique inhal...
... will contribute US$ 74 million for combating tube... Foundation also plans to raise its global funding... 2015. As many as 8 million people across the worl...s the UN publication of the ‘Global Plan to Stop T...
...y is found to cause urinary inconsistence and loss...tudy was conducted by Professor Jeanette S. Brown,...and is reported in Diabetes care. This Diabetes Pr...udy was conducted in 3,234 obese women with pre-di...
...niversity School of Medicine has drafted guideline...the project in Yale University and Pharmaceutical ...etween University and Pharmaceutical Industry. // ...gifts, drugs for personal use, money other than fu...
Other Medicine News:
(Date:11/25/2009)...ORDOVA,Calif.,Nov.25/PRNewswire/--AMPACFineChemica...(Nasdaq: APFC )announcedtodaythatitreceivedtheEnvi...AnnualStatewideEnvironmentalSummit,sponsoredbytheC...A),theIndustrialEnvironmentalAssociation(IEA)andth...nDiego.Thisisthemostprestigiousawardavailablefroma...
(Date:11/25/2009)...,Nov.25/PRNewswire/--Reportlinker.comannouncesthat... ,, UnitedStatesDentalDevicesMarketAnalysisand...m/p0158733/United-States-Dental-Devices-Market-Ana...esDentalDevicesMarketAnalysisandForecaststo2015 ,...orin-depthinformationanddatarelatingtotheUSdentald...
(Date:11/25/2009)...NSWICK,N.J.,Nov.25/PRNewswire/--SwissrayInternatio...aphy( ddR )systems,announcedtodaythatitsoperations...rmviewtowardsgrowingSwissray,smedicalimagingbrand....erty,aswellascontractsandinventory.After25yearsofs...eveloftechnologicaladvancementswithstableandsteady...
Breaking Medicine Technology:AMPAC Fine Chemicals Receives Prestigious Award at California's Annual Statewide Environmental Summit 2Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 2Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 3Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 4Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 5Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 6Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 7Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 8Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 9Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 10Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 11Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 12Swissray International Announces New Ownership 2Infectious Disease News and Infectious Diseases in Children Provide Online Reports Dedicated to Influenza A 28H1N1 29 virus 3A 57444 1Infectious Disease News and Infectious Diseases in Children Provide Online Reports Dedicated to Influenza A 28H1N1 29 virus 3A 57444 2Infectious Disease News and Infectious Diseases in Children Provide Online Reports Dedicated to Influenza A 28H1N1 29 virus 3A 57444 3Teamsters Oppose Baucus Plan to Tax Health Insurance Companies 57442 1Teamsters Oppose Baucus Plan to Tax Health Insurance Companies 57442 2Childrens Hospital of Wisconsin Launches H1N1 Prevention Campaign Geared Toward Children 57440 1Childrens Hospital of Wisconsin Launches H1N1 Prevention Campaign Geared Toward Children 57440 2Childrens Hospital of Wisconsin Launches H1N1 Prevention Campaign Geared Toward Children 57440 3
...harmaceutical,Inc. ("DOV", or the "Company") (OTCB...l Phase Ib results for DOV 21,947, its lead triple...depression and obesity. A,preliminary analysis of ...,safe and well-tolerated at the doses examined, an...n plasma triglyceride levels, as described more,fu...
...e-year follow-up overall,survival data from the X-...show that oral chemotherapy Xeloda(R) (capecitabin...nt - intravenous bolus 5-FU/LV (5-fluorouracil/,le...colon cancer. These,data were presented today at t...lona, Spain. Results show five-year overall survi...
Other Medicine Technology:DOV 21,947 Demonstrates Significant Body Weight and BMI Reductions in Drug- Compliant Subjects in Phase Ib Clinical Study 2DOV 21,947 Demonstrates Significant Body Weight and BMI Reductions in Drug- Compliant Subjects in Phase Ib Clinical Study 3DOV 21,947 Demonstrates Significant Body Weight and BMI Reductions in Drug- Compliant Subjects in Phase Ib Clinical Study 4DOV 21,947 Demonstrates Significant Body Weight and BMI Reductions in Drug- Compliant Subjects in Phase Ib Clinical Study 5Positive Xeloda(R) Five-Year Overall Survival Study Data in the Adjuvant Treatment of Colon Cancer Presented at Leading European Cancer Meeting 2Positive Xeloda(R) Five-Year Overall Survival Study Data in the Adjuvant Treatment of Colon Cancer Presented at Leading European Cancer Meeting 3Positive Xeloda(R) Five-Year Overall Survival Study Data in the Adjuvant Treatment of Colon Cancer Presented at Leading European Cancer Meeting 4
...P Laboratories is a national reference laboratory ...search and development. ARUP offers an extensive t...s in clinical and anatomic pathology. Owned by the...clude more than half of the nation's university te...
...P Laboratories is a national reference laboratory ...search and development. ARUP offers an extensive t...s in clinical and anatomic pathology. Owned by the...clude more than half of the nation's university te...
...P Laboratories is a national reference laboratory ...search and development. ARUP offers an extensive t...s in clinical and anatomic pathology. Owned by the...clude more than half of the nation's university te...
...P Laboratories is a national reference laboratory ...search and development. ARUP offers an extensive t...s in clinical and anatomic pathology. Owned by the...clude more than half of the nation's university te...
Medicine Products: